1H MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines

NMR in Biomedicine

Volumn 20, Issue 7, 2007, Pages 692-700

  Peet, Andrew C ^a   McConville, Carmel ^a   Wilson, Martin ^a   Levine, Barry A ^a   Reed, Michelle ^a   Dyer, Sara A ^b   Edwards, Emma C ^b   Strachan, Mary C ^b   McMullan, Dominic J ^b   Wilkes, Timothy M ^a,c   Grundy, Richard G ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^c LGC   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

1H MRS; Magic angle spinning; Metabolite profiles; MYCN; Neuroblastoma

Indexed keywords

GENETIC ALTERATION; NEUROBLASTOMA;

BIOMARKERS; CELLS; GENES; METABOLITES; PRINCIPAL COMPONENT ANALYSIS; TUMORS;

MAGNETIC RESONANCE SPECTROSCOPY;

CHOLINE KINASE; CREATINE; GLUTAMIC ACID; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; ONCOPROTEIN; PHOSPHORYLCHOLINE; PROTEIN MYCN; TAURINE; UNCLASSIFIED DRUG; CHOLINE; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; METABOLITE; NEUROBLASTOMA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; GENETICS; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CHOLINE; GENE AMPLIFICATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PRINCIPAL COMPONENT ANALYSIS;

EID: 36248980949     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1181     Document Type: Article

References (33)

1. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska N, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman R Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 2005; 10: 2280-2299.
2. Oude Luttikhuis M, Powell J, Rees S, Genus T, Chughtai S, Ramani P, Mann JR, McConville CM. Neuroblastomas with chromosome I I loss and single copy MYCN comprise a biologically distinct group of turnouts with adverse outcome. Br J. Cancer 2001; 85: 531-537.
3. Lastowska M, Cullinane C, Variend S, Cotterill S, Brown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS, United Kingdom Childrens; Cancer Study Group and United Kingdom Cancer Cytogenetics Study Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 2001; 19: 3080-3090.
4. Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Letters 2002; 184: 127-147.
5. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl Acad Sci. USA 2005; 103: 731-736.
6. Alaminos M, Mora J, Cheung NK, Smith A, Qin J, Chen L, Gerald WL. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res. 2003; 63: 4538-4546.
7. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001; 20: 1383-1393.
8. Manohar C, Bray JA, Salwen HR, Madafigilo J, Cheng A, Flenuning C, Marshall GM, Norris MD, Haber M, Cohn SL. MYCN-mediated regultion of the MRP1 promoter in human neuroblastoma. Oncogene 2004; 23: 753-762.
9. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004; 4: 1128-1134.
10. 1H nuclear magnetic resonance spectra by the application of chemometric techniques. Magn. Reson. Med 1992; 28: 214.
11. 1H NMR spectroscopy for three types of human brain and nervous system turnouts. NMR Biomed 1996; 8: 253-264.
12. 1H NMR spectroscopy. NMR Biomed 2002; 15: 375-38.
13. Bhakoo KK, Williams SR, Florian C-L, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996; 56: 4630-4635.
14. Moreno-Torres A, Martinez-Perez I, Baquero M, Campistol J, Capdevila A, Arus C, Pujol J. Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to non-invasive differential diagnosis with cerebellar astrocytoma. Neurosurgery 2004; 55: 824-829.
15. 1H NMR spectroscopy. Cancer Res. 1995; 55: 420-427.
16. Howe FA, Opstad KS. 111 MR spectroscopy of brain tumours and masses. NMR Biomed 2003; 16: 123-131.
17. Lindskog M, Spenger C, Jarvet J, Grasland A, Kogner P. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J. Natl Cancer Inst. 2004; 96: 1457-1466.
18. Ronen SM, Jackosn LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J. Cancer 2001; 84: 691-696.
19. Glunde K, Jie C, Bhujwaller ZM. Molecular causes of aberrant choline phospholipids metabolism in breast cancer. Cancer Res. 2004; 64: 4270-4276.
20. Rodriguez-Gonzalez A, de Molina A, Fernandez F, Ramos MA, Nunez Mdel C, Campos J, Lacal JC. Inhibition of cbotine kinase as a specific cytotoxic strategy in oncogne-transformed cells. Oncogene 2003; 22: 8803-8812.
21. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13: 803-812.
22. Boon K, Caron HN, Van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001; 20: 1383-1393.
23. Spitz R, Hero B, M S Emestus K, Berthold F. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain and non-amplification. Eur J. Cancer 2004; 40: 2753-2759.
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3:34.1-34.11.
25. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shits and coupling constants for brain metabolites. NMR Biomed. 2000; 13: 129-153.
26. 1H MR Spectroscopy of untreated pediatric brain tumours: preoperative diagnosis and characterization. AJNR Am J. Neuroradiol 2006; 27: 560-572.
27. Grandinetti K, Spengler B, Biedler J, Ross R. Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 2006; 25: 706-712.
28. Wharton BA, Morley R, Isaacs EB, Cole TJ, Lucas A. Low plasma taurine and later neurodevelopment. Arch. Dis. Child Fetal Neonatal Ed. 2004; 89: F497-498.
29. Spoerri PE, Caple CG, Roisen FJ. Taurine-induced neuronal differentiation: the influence of calcium and the ganglioside GM1. Int. J. Dev. Neurosci. 1990; 8: 491-503.
30. Beloueche-Babari M, Jackson L, Al-Saffar N, Eccles SA, Reynaud FI, Leach MO, Ronen SM. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol. Cancer Ther. 2006; 5: 187-196.
31. Peet AC, Leach MO, Pinkerton CR, Price P, Williams SR, Grundy RG. The development of functional imaging for the diagnosis, management and understanding of childhood brain tumours: an EPSRC workshop. Pediatr. Blood Cancer 2005; 44: 103-113.
32. 31P MRS in untreated pediatric brain tumours. Magn. Reson. Med. 2005; 53: 22-29.
33. Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer. Eur. J. Cancer 2003; 39: 728-735.